Sun Pharma Q4 Profit Jumps 26% to Rs 2,714 Cr, India Sales Drive Strong FY26 Growth sheeba farhat24 May 2026 11:15 AM ISTNew Delhi: Sun Pharmaceutical Industries Ltd on Friday reported a 26.2 per cent increase in consolidated net profit at Rs 2,714.03 crore in the fourth...
Dilip Shanghvi Calls Sun Pharma's USD 11.75 Billion Organon Deal "Exciting Yet Anxious" Amid Debt Push sheeba farhat28 April 2026 8:13 PM ISTNew Delhi: Sun Pharmaceutical Industries' acquisition of US-based Organon & Co at USD 11.75 billion enterprise valuation is both a "happy" and...
Sun Pharma's Dementia Drug Rivastigmine Banned in China sheeba farhat27 Jan 2026 2:27 PM ISTIn 2024, the USFDA issued a warning letter to Sun Pharma alleging "significant violations" of "current good manufacturing practice" regulations for...
Sun Pharma Names Sana Shaikh as Head of Marketing Parthika Patel20 Jan 2026 9:22 PM ISTNew Delhi: Sun Pharmaceutical Industries Ltd has appointed Sana Shaikh as its Head of Marketing, strengthening the company's leadership as it sharpens...
Sun Pharma Loses Trademark Battle as Bombay HC Finds EsiRaft, Raciraft Not Deceptively Similar Susmita Roy5 Jan 2026 8:31 PM ISTMumbai: The Bombay High Court has set aside the interim injunction granted earlier in the trademark infringement and passing-off dispute between Sun...
Sun Pharma Wins Major CESTAT Relief, Rs 3.9 Cr Excise Demand Set Aside Susmita Roy4 Jan 2026 4:00 PM ISTNew Delhi: In a significant ruling for Export Oriented Units (EOUs), the Customs, Excise and Service Tax Appellate Tribunal (CESTAT), Ahmedabad, has...
NPPA Sets Retail Price For Sun Pharma's Gemcitabine Injections Susmita Roy4 Jan 2026 12:30 PM ISTNew Delhi: The National Pharmaceutical Pricing Authority (NPPA), acting on the recommendations of its Multidisciplinary Committee of Experts (MDC),...
Sun Pharma Gets CDSCO Panel Nod to Market Semaglutide Injection in Weight Loss Indication Susmita Roy1 Jan 2026 5:06 PM ISTNew Delhi: Drug major Sun Pharmaceutical Industries Limited has received a key regulatory clearance from the Subject Expert Committee (SEC)...
No Trial Waiver: CDSCO Panel Directs Sun Pharma to Run Phase III Study for Somatropin Liquid Injection Citing Lack of India-Specific Data Susmita Roy21 Nov 2025 4:26 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has opined that the drug major Sun...
Sun Pharma Told to Limit Phase III Revefenacin Study to Triple Therapy COPD Patients Susmita Roy20 Sept 2025 7:04 PM ISTNew Delhi: Recommending to revise the inclusion criteria so that subjects on triple therapy only shall be included in the study, the Subject Expert...
Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Enzalutamide for Prostate Cancer Susmita Roy3 Sept 2025 1:20 PM ISTNew Delhi: The pharmaceutical major Sun Pharmaceutical Industries has received approval from the Subject Expert Committee (SEC), functional under the...
Sun Pharma Wins CDSCO Panel Approval for Phase III Vitiligo Trial of Ruxolitinib Cream Susmita Roy26 Aug 2025 12:00 PM ISTNew Delhi: Based on the justification presented by the pharmaceutical major Sun Pharmaceutical Industries, the Subject Expert Committee (SEC)...
